Live news related to ADVICENNE stock (FR0013296746): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on ADVICENNE mainly cover M&A activity, earnings publications et analyst notes. The stock trades at €0,63 on Euronext Paris, down 1,56% at the last update. This page lists the articles published on ADVICENNE stock to track the share price, company announcements and any item likely to influence market perception.
In a press release published on October 12, 2026, Advicenne announced that it received the final tranche, amounting to a net €1M, from the bond financ…
Advicenne published its first-half accounts on September 17, 2026, marked by a positive net result of €4.6 million, compared with a loss of €4.96 mill…
The pharmaceutical company specializing in nephrology recorded another severe decline on Wednesday, following the withdrawal of its application for U.…
The pharmaceutical company specializing in nephrology has terminated its American marketing authorization process for its treatment of primary distal …
Advicenne announces the reimbursement approval of Sibnayal (a combination of potassium citrate and bicarbonate) in Spain for the treatment of distal r…
Advicenne announced a net revenue of €2.7M for the first half of 2026, up from €1.03M a year earlier. This significant increase is mainly due to the p…
Advicenne reported a net revenue of €2.7 million in the first half of 2026, up from €1.03 million a year earlier, marking a 170% increase. This growth…
On Wednesday, pharmaceutical company Advicenne announced the indefinite renewal of the marketing authorization (MA) for Sibnayal in the United Kingdom…
Pharmaceutical company Advicenne has announced securing a bond financing of €3.8 million nominal, comprising two tranches subscribed by investors incl…
The Paris-based pharmaceutical company continues its rally in the session, extending a bullish movement that began last week. The stock is challenging…
